-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Adicet Bio, Lowers Price Target to $55

Benzinga·11/06/2026 16:04:22
语音播报
Guggenheim analyst Yatin Suneja maintains Adicet Bio (NASDAQ:ACET) with a Buy and lowers the price target from $90 to $55.